

International Symposium on Albuminuria

**THE ROLE OF ALBUMINURIA IN HEALTH AND DISEASE:
Predicting Outcomes and Target for Therapy**

Please note: This is a draft program and subject to change prior to the meeting. For the most up-to-date program, please contact jenniferm@kidney.org. Attendance at the Symposium is by invitation-only.

Program committee:

Dick de Zeeuw (chair), George Bakris, Gavin Becker, Barry Brenner, Bill Mitch, Marc Pfeffer, Giuseppe Remuzzi, Robert Toto, David Warnock.

Goals:

Primary goal: To present the (global) evidence of the role of albuminuria as an independent marker for renal and cardiovascular disease, as well as an independent therapy target for primary and secondary prevention of renal and cardiovascular disease progression.

Secondary goal: To prepare for a follow up consensus on albuminuria as a target for treatment

Location: Westin Essex House on Central Park
160 Central Park South
New York, New York 10019
United States

Date: May 16-18, 2004

Organizer: National Kidney Foundation (NKF), USA
in association with the International Society of Nephrology (ISN)

Sponsor: The Symposium was made possible by an unrestricted educational grant from AusAm Biotechnologies, Inc.

Supported by:

- American Diabetes Association (ADA)
- American Heart Association (AHA)
- American Society of Hypertension (ASH)
- American Society of Nephrology (ASN)
- International Diabetes Federation (IDF)
- International Society of Nephrology (ISN)
- Juvenile Diabetes Research Foundation (JDRF)
- National Kidney Foundation (NKF), USA

Audience: By invitation: Opinion leaders in cardiology, nephrology, endocrinology, and epidemiology

CONCEPT PROGRAM

Each speaker is allocated 25 minutes for their presentation; following each topic, there will be a discussion period.

Sunday, May 16, 2004

16.30- 21.00	Meeting Registration	
17.00-18.00	Cocktail Reception	
18.00-21.00	Dinner Meeting	Session Chair: Dick de Zeeuw
19.20-19.45	<i>Goal of the meeting</i>	<i>Dick de Zeeuw, Groningen, the Netherlands</i>
19.45-20.10	<i>Risk relation between heart and kidney</i>	<i>Marc Pfeffer, Boston, USA</i>
20.10-20.35	<i>Microalbuminuria versus macroalbuminuria</i>	<i>Giuseppe Remuzzi, Bergamo, Italy</i>
20.35-21.00	<i>Which Albumin should we measure?</i>	<i>Gavin Becker, Melbourne, Australia</i>

Monday, May 17, 2004

07.00	Meeting Registration	
07.00-08.00	Breakfast Buffet	
08.00-10.00	Albuminuria predicting outcome in the general population	Session Chair: Bob Atkins
08.00-08.25	<i>PREVEND</i>	<i>Paul de Jong, Groningen, the Netherlands</i>
08.25-08.50	<i>AusDiab</i>	<i>Bob Atkins, Melbourne, Australia</i>
08.50-09.15	<i>Indigenous</i>	<i>Wendy Hoy, Darwin, Australia</i>
09.15-10.00	GROUP DISCUSSION	
10.00-10.15	Coffee break	
10.15-12.40	Albuminuria predicting outcome in diabetes	Session Chair: Hans-Henrik Parving
10.15-10.40	<i>Incidence of microalbuminuria</i>	<i>Matthew Weir, Baltimore, USA</i>
10.40-11.05	<i>Microalbuminuria, Glycemic Control and Blood Pressure Predicting Outcome in Diabetes Type 1 and Type 2</i>	<i>Carl Erik Mogensen, Aarhus, Denmark</i>
11.05-11.30	<i>Renal and CV outcome (IRMA2 + Steno study)</i>	<i>Hans-Henrik Parving, Gentofte, Denmark</i>
11.30-11.55	<i>Albuminuria and vascular function</i>	<i>Coen Stehouwer, Amsterdam, Netherlands</i>
11.55-12.40	GROUP DISCUSSION	
12.40-13.40	Lunch	
13.40-15.40	Albuminuria predicting outcome in heart disease	Session Chair: Marc Pfeffer
13.40-14.05	<i>Proteinuria CV outcome (INSIGHT)</i>	<i>Luis Ruilope, Madrid, Spain</i>
14.05-14.30	<i>Microalbuminuria CV outcome (LIFE)</i>	<i>Kristian Wachtell & Hans Ibsen, Glostrup, Denmark</i>
14.30-14.55	<i>Microalbuminuria CV outcome (HOPE)</i>	<i>Johannes F. E. Mann, Munchen, Germany</i>
14.55-15.40	GROUP DISCUSSION	
15.40-15.55	Tea break	

15.55-18.35	Mechanism and measurement of albuminuria	Session Chair: Giuseppe Remuzzi
15.55-16.20	<i>Glomerular biochemistry</i>	<i>Karl Tryggvason, Stockholm, Sweden</i>
16.20-16.45	<i>Glomerular mechanism</i>	<i>William Deen, Cambridge, USA</i>
16.45-17.10	<i>New forms of albumin in urine</i>	<i>Wayne Comper, Melbourne, Australia</i>
17.10-17.35	<i>Which Albumin gives what outcome</i>	<i>Stephan Bakker, Groningen, the Netherlands</i>
17.35-18.00	<i>Which urinary protein is damaging</i>	<i>Barry Brenner, Boston, USA</i>
18.00-18.35	GROUP DISCUSSION	

18.35 Meeting adjourns until tomorrow

19.00-21.00 Dinner

Tuesday, May 18, 2004

06.30-07.30 Breakfast Buffet

07.30-09.55	Albuminuria predicting outcome in renal disease	Session Chair: George Bakris
07.30-07.55	<i>Non-diabetic nephropathy (REIN)</i>	<i>Giuseppe Remuzzi, Bergamo, Italy</i>
07.55-08.20	<i>Diabetic (RENAAL)</i>	<i>Bill Mitch, Galveston, USA</i>
08.20-08.45	<i>Diabetic (IDNT)</i>	<i>Larry Hunsicker, Iowa City, USA</i>
08.45-09.10	<i>Hypertensive nephrosclerosis (AASK)</i>	<i>Robert Toto, Dallas, USA</i>
09.10-09.55	GROUP DISCUSSION	

09.55-10.15 Coffee break

10.15-12.30	Albuminuria as a therapy target for renal-CV protection	Session Chair: Robert Toto
10.15-10.40	<i>Treatment options</i>	<i>Mark Cooper, Melbourne, Australia</i>
10.40-11.05	<i>Albuminuria reduction and CV protection (PREVEND-IT)</i>	<i>Wiek van Gilst, Groningen, the Netherlands</i>
	<u>Pharmacoeconomics of prevention:</u>	
11.05-11.30	<i>RENAAL</i>	<i>Charles M. Alexander, West Point, USA</i>
11.30-11.55	<i>IRMA2 + IDNT</i>	<i>Roger Rodby, Chicago, USA</i>
11.55-12.30	GROUP DISCUSSION	

12.30-13.30 Lunch

13.30-16.10	Inclusion of albumin as a target in therapy guidelines	Session Chair: Tom Hostetter*
13.30-13.55	<i>Renal patient guidelines</i>	<i>David Warnock, Birmingham, USA</i>
13.55-14.20	<i>Hypertension/Diabetic/Heart patient guidelines</i>	<i>George Bakris, Chicago, USA</i>
14.20-14.45	<i>Government point of view (NIH)</i>	<i>Tom Hostetter, Bethesda, USA</i>
14.45-15.10	<i>A USA regulator's view (FDA)</i>	<i>Ethan Hausman, Rockville, USA</i>
15.10-15.35	<i>A European regulator's view (EMEA)</i>	<i>Gonzalo Calvo and Fernando de Andres-Trelles, Barcelona, Spain</i>
15.35-16.10	GROUP DISCUSSION	

16.10-16.55 Summary and Conclusion *Barry Brenner, Boston, USA*

16.55 Meeting Adjourns